Actinogen Medical's drug Xanamem demonstrated meaningful antidepressant activity in a Phase 2 trial involving patients with difficult-to-treat major depressive disorder. The study showed significant improvement in depression symptoms, especially among those also on selective serotonin reuptake inhibitors, with benefits increasing over time. Xanamem was safe and well tolerated, though it did not show additional cognitive benefits over placebo. The drug is also being tested for Alzheimer's disease, with key trial results expected in November 2026, potentially offering a novel treatment option for depression and Alzheimer's-related symptoms.
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on July 23, 2026. The bank purchased 640,099 ordinary shares at prices between 280 and 280.25 per unit and sold 650,000 sh...
West Pharmaceutical Services reported strong 2Q26 results with revenue of $872.3M, up 13.8% year-over-year, and adjusted EPS of $2.37, beating consensus by $0.29. The company raised its full-year guidance to $3.345–$3.380 billion in sales and $8.85–$...
Circle, the issuer of the USDC stablecoin, minted 250 million new USDC tokens, adding to the circulating supply. This minting event is part of Circle's routine process to align token supply with dollar reserves and meet demand. While such large mints...
